Y-K. Kang

919 total citations
39 papers, 749 citations indexed

About

Y-K. Kang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Y-K. Kang has authored 39 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 14 papers in Surgery. Recurrent topics in Y-K. Kang's work include Gastric Cancer Management and Outcomes (21 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Esophageal Cancer Research and Treatment (8 papers). Y-K. Kang is often cited by papers focused on Gastric Cancer Management and Outcomes (21 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Esophageal Cancer Research and Treatment (8 papers). Y-K. Kang collaborates with scholars based in South Korea, United States and Japan. Y-K. Kang's co-authors include M.-H. Ryu, Jia-Lin Lee, B-Y. Ryoo, Heung-Moon Chang, Tae‐Won Kim, L-T. Chen, Narikazu Boku, Kyung-Woo Lee, Young Joo Min and J G Kim and has published in prestigious journals such as Blood, Journal of Hepatology and British Journal of Cancer.

In The Last Decade

Y-K. Kang

39 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y-K. Kang South Korea 15 476 454 229 177 131 39 749
Marine Jary France 17 343 0.7× 439 1.0× 265 1.2× 102 0.6× 115 0.9× 52 796
Hye Jin Kang South Korea 12 480 1.0× 526 1.2× 467 2.0× 94 0.5× 80 0.6× 36 853
Giovanni Randon Italy 16 361 0.8× 673 1.5× 183 0.8× 65 0.4× 140 1.1× 51 915
Takeshi Kajiwara Japan 14 388 0.8× 436 1.0× 292 1.3× 69 0.4× 94 0.7× 69 868
Masako Asayama Japan 14 345 0.7× 766 1.7× 288 1.3× 190 1.1× 81 0.6× 41 1.0k
M Findlay United Kingdom 6 659 1.4× 511 1.1× 361 1.6× 167 0.9× 106 0.8× 8 890
Madoka Hamada Japan 17 239 0.5× 401 0.9× 370 1.6× 88 0.5× 86 0.7× 64 681
Axel Wein Germany 12 204 0.4× 307 0.7× 225 1.0× 72 0.4× 58 0.4× 40 573
Ludovic Evesque France 14 449 0.9× 648 1.4× 447 2.0× 155 0.9× 53 0.4× 57 1.1k
Takashi Ichimura Japan 12 274 0.6× 361 0.8× 143 0.6× 56 0.3× 96 0.7× 52 579

Countries citing papers authored by Y-K. Kang

Since Specialization
Citations

This map shows the geographic impact of Y-K. Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y-K. Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y-K. Kang more than expected).

Fields of papers citing papers by Y-K. Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y-K. Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y-K. Kang. The network helps show where Y-K. Kang may publish in the future.

Co-authorship network of co-authors of Y-K. Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Y-K. Kang. A scholar is included among the top collaborators of Y-K. Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y-K. Kang. Y-K. Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sangro, Bruno, George Lau, Masatoshi Kudo, et al.. (2023). 147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 34. S1530–S1531. 1 indexed citations
3.
4.
Ajani, Jaffer A., Y-K. Kang, Simon Allen, et al.. (2021). 1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer. Annals of Oncology. 32. S1047–S1047. 1 indexed citations
5.
Catenacci, Daniel V.T., Byoung Yong Shim, S.T. Kim, et al.. (2021). 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A. Annals of Oncology. 32. S1043–S1044. 13 indexed citations
6.
7.
8.
9.
Sangro, Bruno, Ignacio Melero, Chiun Hsu, et al.. (2017). Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040. UCL Discovery (University College London). 12 indexed citations
10.
11.
Choo, Su Pin, Thomas Yau, Chih‐Hung Hsu, et al.. (2017). Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study. Annals of Oncology. 28. x57–x58. 1 indexed citations
12.
13.
Sarker, Debashis, Teresa Macarulla, Thomas Yau, et al.. (2017). Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. v122–v122. 17 indexed citations
14.
15.
16.
Kang, Y-K., Changhoon Yoo, B-Y. Ryoo, et al.. (2013). Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. British Journal of Cancer. 109(9). 2309–2315. 49 indexed citations
17.
Lee, Jia-Lin, M.-H. Ryu, Heung Moon Chang, et al.. (2012). Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. British Journal of Cancer. 106(10). 1591–1597. 13 indexed citations
18.
Jang, Geundoo, Kyun‐Seop Bae, Hei Sung Kim, et al.. (2011). Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. British Journal of Cancer. 104(4). 605–612. 25 indexed citations
19.
Lordick, Florian, et al.. (2007). HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. mediaTUM (Technical University of Munich). 25 indexed citations
20.
Chang, Heung-Moon, Tae‐Won Kim, M.-H. Ryu, et al.. (2005). Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. British Journal of Cancer. 92(2). 246–251. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marine Jary Breakdown of academic impact, for papers by Hye Jin Kang Breakdown of academic impact, for papers by Giovanni Randon Breakdown of academic impact, for papers by Takeshi Kajiwara Breakdown of academic impact, for papers by Masako Asayama Breakdown of academic impact, for papers by M Findlay Breakdown of academic impact, for papers by Madoka Hamada Breakdown of academic impact, for papers by Axel Wein Breakdown of academic impact, for papers by Ludovic Evesque Breakdown of academic impact, for papers by Takashi Ichimura
Rankless by CCL
2026